PURPOSE: Cigarette smoking is a risk factor for developing nonmuscle invasive bladder cancer, and continued smoking exposure after diagnosis may increase the likelihood of adverse clinical outcomes. We compare self-reported vs biochemically verified nicotine exposure to determine the accuracy of self-report among recently diagnosed nonmuscle invasive bladder cancer patients. MATERIALS AND METHODS: This cross-sectional analysis consisted of 517 nonmuscle invasive bladder cancer patients who contributed a urine or saliva specimen the same day as self-reporting their smoking, use of e-cigarettes, nicotine replacement therapy and whether they lived with a smoker. Cotinine, the primary metabolite of nicotine, was used as an objective biomarker of recent nicotine exposure. RESULTS: The prevalence of high, low and no cotinine exposure was 13%, 54% and 33%, respectively. Overall, 7.3% of patients (38/517) reported being a current cigarette smoker, while 13% (65/517) had cotinine levels consistent with active smoking exposure. Of these 65 patients 27 denied current smoking, resulting in a sensitivity of self-reported current smoking of 58%. After considering other sources of nicotine exposure such as e-cigarettes, cigars, nicotine replacement therapy and living with a smoker, the sensitivity was higher, at 82%. Nearly all patients with low cotinine denied any smoking-related exposure. CONCLUSIONS: Our findings suggest either biochemical verification with cotinine or additional questions about other sources of nicotine are needed to accurately identify nonmuscle invasive bladder cancer patients who have smoking-related exposures. Accurate classification of active and passive smoking exposure is essential to allow clinicians to advise cessation and help researchers estimate the association between post-diagnosis smoking-related exposure and nonmuscle invasive bladder cancer recurrence risk.
PURPOSE: Cigarette smoking is a risk factor for developing nonmuscle invasive bladder cancer, and continued smoking exposure after diagnosis may increase the likelihood of adverse clinical outcomes. We compare self-reported vs biochemically verified nicotine exposure to determine the accuracy of self-report among recently diagnosed nonmuscle invasive bladder cancer patients. MATERIALS AND METHODS: This cross-sectional analysis consisted of 517 nonmuscle invasive bladder cancer patients who contributed a urine or saliva specimen the same day as self-reporting their smoking, use of e-cigarettes, nicotine replacement therapy and whether they lived with a smoker. Cotinine, the primary metabolite of nicotine, was used as an objective biomarker of recent nicotine exposure. RESULTS: The prevalence of high, low and no cotinine exposure was 13%, 54% and 33%, respectively. Overall, 7.3% of patients (38/517) reported being a current cigarette smoker, while 13% (65/517) had cotinine levels consistent with active smoking exposure. Of these 65 patients 27 denied current smoking, resulting in a sensitivity of self-reported current smoking of 58%. After considering other sources of nicotine exposure such as e-cigarettes, cigars, nicotine replacement therapy and living with a smoker, the sensitivity was higher, at 82%. Nearly all patients with low cotinine denied any smoking-related exposure. CONCLUSIONS: Our findings suggest either biochemical verification with cotinine or additional questions about other sources of nicotine are needed to accurately identify nonmuscle invasive bladder cancer patients who have smoking-related exposures. Accurate classification of active and passive smoking exposure is essential to allow clinicians to advise cessation and help researchers estimate the association between post-diagnosis smoking-related exposure and nonmuscle invasive bladder cancer recurrence risk.
Authors: Anne J Grotenhuis; Cornelis W Ebben; Katja K Aben; J Alfred Witjes; Alina Vrieling; Sita H Vermeulen; Lambertus A Kiemeney Journal: Urol Oncol Date: 2014-07-09 Impact factor: 3.498
Authors: Michael Rink; Helena Furberg; Emily C Zabor; Evanguelos Xylinas; Marko Babjuk; Armin Pycha; Yair Lotan; Pierre I Karakiewicz; Giacomo Novara; Brian D Robinson; Francesco Montorsi; Felix K Chun; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2012-08-21 Impact factor: 20.096
Authors: Nelson A Morales; Michelle A Romano; K Michael Cummings; James R Marshall; Andrew J Hyland; Alan Hutson; Graham W Warren Journal: Cancer Causes Control Date: 2013-04-04 Impact factor: 2.506
Authors: Teresa W Wang; Kat Asman; Andrea S Gentzke; Karen A Cullen; Enver Holder-Hayes; Carolyn Reyes-Guzman; Ahmed Jamal; Linda Neff; Brian A King Journal: MMWR Morb Mortal Wkly Rep Date: 2018-11-09 Impact factor: 17.586
Authors: Alan E Thong; Stacey Petruzella; Irene Orlow; Emily C Zabor; Behfar Ehdaie; Jamie S Ostroff; Bernard H Bochner; Helena Furberg Barnes Journal: Eur Urol Focus Date: 2015-12-19
Authors: Ahmed Jamal; Elyse Phillips; Andrea S Gentzke; David M Homa; Stephen D Babb; Brian A King; Linda J Neff Journal: MMWR Morb Mortal Wkly Rep Date: 2018-01-19 Impact factor: 17.586
Authors: Helena Furberg; Stacey Petruzella; Karissa Whiting; Emily Stein; Irene Orlow; Jessica Kenney; Sergio Corrales-Guerrero; Nicole Benfante; Eugene K Cha; Timothy F Donahue; Sherri M Donat; Harry W Herr; Richard S Matulewicz; Eugene Pietzak; Guido Dalbagni; Jamie Ostroff; Bernard H Bochner Journal: J Urol Date: 2022-01-27 Impact factor: 7.600